Irish entrepreneurs grapple with complexities of 'endlessly fascinating' South Africa – The Irish Times
EY Entrepreneur of the Year finalists visit Cape Town ahead of crucial, historic general election next week
Source: irishtimes.com
:quality(70):focal(1148x1047:1158x1057)/cloudfront-eu-central-1.images.arcpublishing.com/irishtimes/HS3ESLOZQVFJPPKM62UI2VGPNI.jpg)
Orlaith Ryan News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Orlaith Ryan. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Orlaith Ryan Today - Breaking & Trending Today
2024 EY Entrepreneur of the Year Award Finalists Panel
This year’s finalists in the EY Entrepreneur have just been announced and it’s a bumper group...
Source: newstalk.com
:quality(70):focal(902x485:912x495)/cloudfront-eu-central-1.images.arcpublishing.com/irishtimes/BW2H7ZXCCZCA7K7NPYYMEGSCOA.jpg)
Shortlist for 2024 EY Entrepreneur of the Year awards revealed
Finalists will compete across three main categories over 10-month programme
Source: irishtimes.com
Shorla Oncology Announces FDA Filing Acceptance of New Drug Application to Treat Certain Forms of Leukemia and Other Cancers
CAMBRIDGE, Mass., April 08, 2024--Shorla Oncology (‘Shorla’), a U.S.-Ireland specialty pharmaceutical company, announced today that the U.S. Food and Drug Administration (FDA) has accepted for review the company’s New Drug Application (NDA) for SH-201, the first palatable oral liquid of the related chemotherapeutic agent to treat certain forms of leukemia and other cancers. The Agency assigned a Prescription Drug User Fee Act ("PDUFA") action date of November 30, 2024.
Source: yahoo.com
FDA Accepts NDA for SH-201 in Leukemia and Other Cancers
The FDA has accepted for review the new drug application for SH-201 for the treatment of patients with certain forms of leukemia and other cancers.
Source: onclive.com